​

Verve Therapeutics (VERV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

VERV Stock Forecast

Verve Therapeutics (VERV) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $14.00, with a high of $14.00 and a low of $14.00. This represents a 81.82% increase from the last price of $7.70.

- $4 $8 $12 $16 $20 High: $14 Avg: $14 Low: $14 Last Closed Price: $7.7

VERV Stock Rating

Verve Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (62.50%), 2 Hold (25.00%), 1 Sell (12.50%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 1 2 5 Strong Sell Sell Hold Buy Strong Buy

VERV Forecast vs Benchmarks

TypeNameUpside
StockVerve Therapeutics81.82%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$14.00$22.00
Last Closing Price$7.70$7.70$7.70
Upside/Downside-81.82%185.71%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25352--10
Dec, 24352--10
Nov, 24462--12
Oct, 24462--12
Sep, 24462--12
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 06, 2024Mitchell KapoorH.C. Wainwright$14.00$6.32121.52%81.82%
Apr 03, 2024Kostas BiliourisBMO Capital$30.00$8.57250.06%289.61%
Dec 15, 2022Goldman Sachs$13.00$22.61-42.50%68.83%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Nov 06, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2024RBC CapitalOutperformOutperformhold
May 09, 2024JefferiesBuyBuyhold
Apr 08, 2024H.C. WainwrightBuyinitialise
Apr 03, 2024BMO CapitalOutperformOutperformhold
Apr 02, 2024RBC CapitalOutperformOutperformhold
Feb 01, 2023Cantor FitzgeraldNeutralinitialise
Dec 15, 2022Goldman SachsSellinitialise
Oct 06, 2022Credit SuisseNeutralinitialise
Aug 25, 2022Telsey AdvisoryBuyupgrade

Financial Forecast

EPS Forecast

$-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.87$-3.12-----
Avg Forecast$-2.94$-3.16$-2.43$-2.81$-2.91$-2.90$-3.38
High Forecast$-3.98$-3.51$-2.61$-3.38$-3.82$-3.69$-4.61
Low Forecast$-1.81$-3.00$-2.26$-2.52$-2.22$-2.15$-1.51
Surprise %201.70%-1.27%-----

Revenue Forecast

$0 $9M $18M $27M $36M $45M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.94M$11.76M-----
Avg Forecast$1.21M$11.15M$23.82M$14.57M$9.98M$34.00M$13.60M
High Forecast$846.97K$8.57M$19.46M$8.35M$5.72M$19.50M$7.80M
Low Forecast$1.53M$14.45M$29.94M$18.65M$12.78M$43.53M$17.41M
Surprise %61.08%5.47%-----

Net Income Forecast

$-300M $-250M $-200M $-150M $-100M $-50M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-157.39M$-200.07M-----
Avg Forecast$-188.89M$-200.07M$-156.29M$-189.29M$-193.76M$-187.18M$-216.91M
High Forecast$-255.55M$-225.08M$-167.25M$-216.97M$-244.96M$-236.54M$-295.92M
Low Forecast$-115.93M$-192.40M$-145.33M$-161.61M$-142.57M$-137.82M$-96.62M
Surprise %-16.68%------

VERV Forecast FAQ

Is Verve Therapeutics stock a buy?

Verve Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 2 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Verve Therapeutics is a favorable investment for most analysts.

What is Verve Therapeutics's price target?

Verve Therapeutics's price target, set by 8 Wall Street analysts, averages $14 over the next 12 months. The price target range spans from $14 at the low end to $14 at the high end, suggesting a potential 81.82% change from the previous close price of $7.7.

How does Verve Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Verve Therapeutics stock forecast shows a 81.82% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Verve Therapeutics over the past three months?

  • January 2025: 30.00% Strong Buy, 50.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 30.00% Strong Buy, 50.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 33.33% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Verve Therapeutics’s EPS forecast?

Verve Therapeutics's average annual EPS forecast for its fiscal year ending in December is -2.43 for 2024, a -22.12% decrease from the reported $-3.12 in 2023. The prediction for 2025 is $-2.81, $-2.91 for 2026, $-2.9 for 2027, and $-3.38 for 2028.

What is Verve Therapeutics’s revenue forecast?

Verve Therapeutics's average annual revenue forecast for its fiscal year ending in December is $23.82M for 2024, a 102.62% increase from the reported $11.76M in 2023. The forecast for 2025 is $14.57M, $9.98M for 2026, $34M for 2027, and $13.6M for 2028.

What is Verve Therapeutics’s net income forecast?

For its fiscal year ending in December, Verve Therapeutics's average annual net income forecast is $-156M for 2024, reflecting a -21.88% decrease from the reported $-200M in 2023. The projection for 2025 is $-189M, $-194M for 2026, $-187M for 2027, and $-217M for 2028.